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Abstract
While insulin replacement remains the cornerstone treatment for type I diabetes mellitus (T1DM),
the transplantation of pancreatic islets of Langerhans has the potential to become an important
alternative. And yet, islet transplant therapy is limited by several factors, including far too few donor
pancreases. Attempts to expand mature islets or to produce islets from stem cells are far from
clinical application. The production and expansion of the insulin-producing cells within the islet (so
called β cells), or even creating cells that secrete insulin under appropriate physiological control,
has proven difficult. The difficulty is explained, in part, because insulin synthesis and release is
complex, unique, and not entirely characterized. Understanding β-cell function at the molecular
level will likely facilitate the development of techniques to manufacture β-cells from stem cells. We
will review islet transplantation, as well as the mechanisms underlying insulin transcription,
translation and glucose stimulated insulin release.
Background
Insulin, the body's only blood glucose-lowering hor-
mone, is exclusively produced by the β-cells of the pancre-
atic islets of Langerhans. Type I diabetes mellitus (T1DM),
formerly known as insulin-dependent diabetes or juvenile
diabetes, affects an estimated 1,000,000 Americans, and is
thought to result from the destruction of β cells by autol-
ogous cytotoxic T cells. The discovery of insulin in the
1920's was a major advance in diabetes treatment – free-
ing patients from the then "state of the art" starvation
diets that, at best, prolonged survival for a few weeks,
months, or in very rare cases, a few years. Insulin therapy
changed diabetes from a rapidly fatal disease to a chronic
disease associated with significant secondary complica-
tions, such as renal failure, neuropathy, cardiovascular
disease, and retinopathy. While aggressive insulin therapy
that maintains glucose levels near the normal range
reduces the risk of secondary complications, patients
often find such control difficult to achieve and suffer an
increased risk of hypoglycemia [1]. Nonetheless, T1DM
treatment has significantly improved with affordable glu-
cose monitoring instruments, new insulin formulations,
and improved insulin delivery systems.
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Transplantation
Many clinical investigators have attempted β-cell replace-
ment therapy, either in the form of whole pancreas or islet
transplantation. Whole pancreas transplantation was first
performed in the 1960s, but was a relatively uncommon
procedure until the 1980's. From December 16, 1966 to
December 31, 2004, more than 23,000 pancreas trans-
plants were reported to the International Pancreas Trans-
plant Registry (IPTR), including > 17000 from the US and
almost 6000 from outside the US. The annual number of
US in 2004 was close to 1500 [2]. The procedure's increas-
ing popularity can be ascribed to improvements in organ
preservation, surgical technique, and immunosuppressive
therapy.
Patients given a pancreas transplant, at experienced cent-
ers, currently can anticipate a greater than 85% likelihood
that they will enjoy insulin independent euglycemia 1
year later, and about 50% will maintain that excellent
metabolic outcome 5 years following the transplant.
While most pancreas transplant recipients no longer
require exogenous insulin for blood glucose control, the
procedure has not been shown to decrease the severity or
frequency of the secondary complications associated with
diabetes. For instance, while pancreas transplant has been
shown to reverse histologically defined diabetic nephrop-
athy ten years after transplantation, only a minority of
grafts survive that long, and the immunosuppression
given to preserve the transplanted organ may be more
nephrotoxic than the diabetes prompting the transplant
[3]. In fact, whether pancreas transplant alone offers any
survival advantage versus insulin therapy alone is
debated, and transplant recipient survival may even be
worse [4,5].
While pancreas transplantation has yielded promising
results, other investigators have worked to develop iso-
lated islet transplantation. Islet transplantation is poten-
tially appealing because the transplant technique does not
require major surgery. Using animal models in the 1970s,
islets were first isolated from the pancreas and effectively
transplanted [6]. Preliminary human islet cell transplant
reports appeared in the late 1970's [7,8]. Islet transplanta-
tion was not used clinically to treat type I diabetes until
1989 [9].
Although successful procedure of living-donor transplan-
tation of islets has been reported [10], in its current status,
most islet transplants involve the isolation of islets from
cadaveric (deceased) donor organs. The isolation process
entails both enzymatic (using collagenase) and mechani-
cal disruption of a cadaveric pancreas into small frag-
ments. Islets are then purified from the remaining
exocrine tissue by density gradient separation [11]. Once
"purified" (and isolated islets should more accurately be
termed "enriched" because exocrine pancreatic fragments
are also nearly always present), the islets are infused into
the recipient's portal vein where they lodge in the liver's
portal vein tree. Islets have been introduced into the por-
tal circulation through the umbilical vein, but percutane-
ous transhepatic angiographic infusion is now used most
frequently. Isolated islets are usually infused within 48
hours (some centers infuse them within hours), and most
recipients require islets from more than one cadaver. The
islets isolated from one cadaver are typically given with
each infusion, such that most islet recipients end-up
requiring two or more islet infusions. While islet infu-
sions are generally well tolerated, they can be complicated
by (at least temporary) portal hypertension, thrombosis
or hemorrhage.
Before 2000, the preceding 2 decades of islet transplanta-
tion by investigators world-wide, had achieved 1-year
insulin independence rates of less than 12% [12]. How-
ever, in 2000 the group from the University of Alberta,
Edmonton reported that their protocol for islet transplan-
tation and immunosuppression significantly improved
graft function [13]. The Edmonton protocol used a ster-
oid-free immunosuppressive regimen and high quality
islet cells from 2 or more donors. The quality of islet cells
obtained from each cadaver was improved by limiting
cold ischemia time to 8 hours prior to initiating the isola-
tion procedure and using a standardized collagenase prep-
aration. Further, the Edmonton group transplanted the
isolated islets, as soon as possible following the isolation,
via transhepatic angiography. To prevent islet allograft
rejection, the Edmonton team avoided glucocorticoids by
giving the recipient induction immunosuppression with
the anti- IL-2 receptor antibody (daclizumab), then more
chronic immunosuppression was initiated with sirolimus
(rapamycin) and tacrolimus (FK-506) [14,15]. Recently,
an international, multicenter trial tested whether islet
transplantation using the Edmonton protocol could be
generalized. From more than 2000 with T1DM expressing
an interest in the protocol, 36 patients were selected and
given allogeneic islets. Sixteen of the 36 (44%) attained
the primary end point of insulin independence (defined
as a fasting blood glucose not to exceed 140 mg/dl more
than 3x/week, and a 2 hour post-prandial blood glucose
not to exceed 180 mg/dl more than 4x/week), 28% had
partial graft function and 28% had complete graft loss.
While many of the insulin independent subjects did not
have normal blood glucose values by currently accepted
criteria, the subjects who reached the primary end point
had no severe hypoglycemia or severe hyperglycemia, and
those with partial function had a marked benefit in glyc-
emia control in contrast to their baseline status [16].
Unfortunately, and for reasons not well understood, only
14% of the subjects remained insulin independent 2 years
after receiving an islet transplant. Further, the currentJournal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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immunosuppressive regimen is associated with height-
ened risk of infection, β cell toxicity, and (most impor-
tantly) nephropathy such that the protocol participants
lost, on average about 5% of their kidney function each
year.
Alternative sources of β Islets
While pancreas and islet cell transplants have the poten-
tial to treat many patients with diabetes, these transplants
require the collection of pancreata from organ donors
[13,17], and donors are very limited. Optimistic estimates
suggest that in a typical year and using current techniques,
islets isolated form U.S. cadaveric pancreata could trans-
plant at most 1,000 to 2,000 patients [14]. In order to
treat more patients, the field needs an alternative source of
cells capable of physiologically regulated insulin secre-
tion. Transplanting cells generated from stem cells is one
potential treatment alternative [18] and another is the
expansion adult islet β cells, xenogeneic islet is considered
another alternative source.
While a stem cell that could be isolated from the pancreas,
expanded, and differentiated in vitro into mature beta-like
cells may exist, such a cell has not yet been identified [19],
and culture techniques have not been perfected. If such a
cell could be isolated from the pancreas and expanded in
vitro, it is possible that enough islets could be produced
from a pancreas from a single donor for one or more suc-
cessful transplants.
Another alternative is to produce β cells from stem cells.
Several groups have attempted to differentiate embryonic
stem cells into β cells, but none has yet been successful.
Islet-like cells have been generated from embryonic stem
cells, but the cells do not secrete insulin in a physiologi-
cally regulated fashion [20]. In vitro differentiation of
embryonic stem cells is to mimic normal embryonic
development, the exposure of stem cells to growth factors,
extracellular matrix components, and cell-cell interactions
may promote and streamline the differentiation process.
The existing protocols for generating insulin-producing
cells from embryonic stem cells can be divided into spon-
taneous differentiation and induced differentiation. The
efficiency of the former protocol is too low to be of prac-
tical value [21-23] and induced differentiation is the
mainstream. Lumelsky modified a protocol used to gener-
ate neurons from mouse embryonic stem cells and
obtained insulin-producing cells [24], their results were
repeated by other groups [25,26]. However, some reports
showed that the cells can not produce insulin themselves,
but rather absorb insulin from the culture medium while
undergoing apoptosis [27]. Recently, D'Amour developed
a five-stage protocol to differentiate human embryonic
stem cells to endocrine hormone-expressing cells through
a series of endodermal intermediates resembling those
that occur during pancreatic development in vivo [28].
Despite the facts, the procedure of pancreas development
is so complex and precise that many aspects are not well
understood now. Fortunately, advances in high-through-
out technology such as microarray technology will facili-
tate the discovery of regulating network of pancreatic
development, which will provide more information to
better direct differentiating stem cells.
Adult stem cells are another potential source of islets [18].
Some animal hematopoietic transplant models have sug-
gested that adult pluripotential stem cells from bone mar-
row can be induced to transdifferentiate into β-like cells,
but subsequent studies have suggested that the cells were
the result of cell-to-cell fusion rather than transdifferenti-
ation [29]. It may also be possible to generate insulin pro-
ducing cells using gene therapy. Some studies have
suggested that transfecting hepatocytes with the gene
encoding PDX-1 resulted in an insulin producing cell, but
those results have not been widely reproduced [30-32].
Xenogeneic islets is another alternative; a couple of papers
were recently published in Nature Medicine showing that
porcine islets xenografts can succeed and has potential for
clinical application [33,34]. However, xenogeneic trans-
plants take major immunosuppression which signifi-
cantly outweighs the risk of diabetes and the results were
not consistent, several of the grafts failed early.
While all of these potential therapies are promising, none
is yet useful clinically. Furthermore, since β cell insulin
release to control glucose levels is both very complex and
precise, it is likely that any cultured, expanded, or other-
wise manufactured cells will have to function with β cell-
like precision. We suggest therefore that it will not be pos-
sible to create highly effective expanded, cultured or man-
ufactured β cells until the mechanisms responsible for
glucose-induced β cell insulin synthesis and release are
completely understood and these functions can be dupli-
cated.
Insulin transcription, translation, and release
The production of insulin and its release from islets is
complex and tightly regulated. Glucose affects insulin at
all levels, including transcription, translation and release.
Transcription
Insulin is encoded by the insulin gene located on chromo-
some 11p15.5 [35]. Insulin expression is restricted to the
β cell and insulin transcription is controlled by the insulin
promoter, and in particular a highly conserved 340 bp
region located immediately upstream from the transcrip-
tion initiation start site [36]. The insulin promoter is
responsible for tissue specific and metabolic regulation of
the insulin gene. The most critical transcription activationJournal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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elements of the insulin promoter are the A3, C1 and E1
sites.
The most important insulin transcription factor is the
homeodomain transcription factor pancreatic/duodenal
homebox-1 (PDX-1). In the adult islet, PDX-1 is only
expressed in the pancreatic β cells and plays an important
role in glucose-stimulated insulin gene transcription.
PDX-1 is also essential for maintenance of the β cell phe-
notype and pancreatic development [36,37]. PDX-1 binds
to the A3 box of the insulin promoter. Alone PDX-1 has
little activity, but it becomes a potent factor when it inter-
acts with the heterodimer of basic helix-loop-helix
(bHLH) proteins which bind to the E1 box. These bHLH
heterodimers are made up of a Class A bHLH protein
which is expressed ubiquitously in many different tissues
and a Class B bHLH protein that is specifically expressed
in β cells. The members of the class A bHLH family in the
heterodimer that binds to the E1 site are products of the
E2A gene; E12, E47, and E2/5 and the class B bHLH pro-
tein BETA2/NeuroD. The heterodimer E47/BETA2 is
found in β cells.
Another important insulin transcription factor is MafA
which belongs to the Maf family of transcription factors.
This family of transcription factors contains a basic motif
followed by a leucine zipper. In addition, MafA also con-
tains an acidic domain that acts as a transcription initia-
tion domain [38]. MafA binds to the C1 site of the insulin
promoter. MafA is a glucose-regulated and pancreatic β
cell-specific transcriptional activator for the insulin gene
[39-41], which produces synergistic activation with PDX-
1 or BETA2.
In addition to PDX1, E47/BETA2/NeuroD, and MafA,
other factors influence insulin transcription. Histones and
DNA-binding proteins of the high mobility group (HMG)
increases the binding of PDX-1 and bHLH heterodimers
to the A and E sites. One important HMG protein is HMG
1(Y) which binds to the A3/A4 site of the insulin pro-
moter [37]. Other proteins that contribute to insulin tran-
scription include members of the hepatic nuclear factors
and PAX families [36] (Figure 1).
Insulin synthesis
Translating the insulin mRNA leads to preproinsulin pro-
duction. Approximately 30 to 60 seconds after preproin-
sulin is synthesized in the ER, the pre portion is removed
enzymatically and proinsulin is transported along the
microtubule network system in transport vesicles to the
cis part of the Golgi apparatus. The proinsulin was first
packaged into clathrin-coated immature granules, where
proinsulin is further converted to insulin and C-peptide
[42]. The clathrin-coated granules then become mature
granules, where the insulin crystals are formed; thus the
insulin is stored in the mature secretory granules until it is
either released by exocytosis or degraded by crinophagy
[43].
The β cell has highly developed ER specialized for the syn-
thesis of insulin. β Cells can control the rate of insulin
production by regulating insulin synthesis in the ER in
response to glucose stimulation. Eukaryotic initiation fac-
tor 2 (eIF2) is an important factor regulating protein bio-
synthesis. The eIF2 factor participates in the formation of
translational ternary complex (eIF2-GTP·Met-tRNAi),
recruiting charged initiator methionyl-tRNA to the 40S
ribosomal subunit. The activity of the eIF2 complex is
dependent on its state of phosphorylation. Pancreatic ER
kinase (PERK), an important regulator of insulin transla-
tion in β cells, phosphorylates eIF2 complex and hence
lowers insulin translation [44]. PERK activity is sensitive
to glucose levels [45]. Therefore, PERK signaling is partic-
ularly important to normal β cell function.
The initiation complex eIF4F initiates the recruitment of
the 40S ribosome to mRNA in insulin synthesis. Hypo-
phosphorylated eIF4E-binding proteins (4E-BPs) inhibit
eIF4F complex formation, but phosphorylation of 4E-BP1
The promoter region of insulin gene Figure 1
The promoter region of insulin gene. The organization 
of the proximal portion (-340 bp to +1 bp) of the insulin pro-
moter including critical transcription activation elements and 
their binding transcription factors are shown. The critical 
transcription activation elements are illustrated as boxes. 
Above the boxes are shown the names of transcription fac-
tors that can bind to corresponding elements. Elements A3, 
C1, E1 have been implicated in β cell-specific expression of 
the insulin gene, which is mediated by the restricted cellular 
distribution of their transcription factors PDX-1, MafA, Beta-
2. The synergistic activities of PDX-1, MafA and Beta-2 are 
illustrated by green arrows. In addition to transcription fac-
tors, DNA-binding proteins such as HMG I (Y) can promote 
the binding of PDX-1 and Beta2/E47 to their corresponding 
elements.Journal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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leads to loss of this inhibition, therefore inducing an
increase in mRNA translation [46,47].
Insulin release
Nearly all insulin released by β cells is from insulin secre-
tory granules. To release insulin, the granules must be
recruited from the cytoplasm, translocated to the plasma
membrane where they are docked, fuse with the plasma
membrane, and release their contents into the extracellu-
lar space. A group of proteins known as the SNAp REcep-
tors (SNARES) are important for directing the insulin
vesicles to the plasma membrane. The actual docking of
the vesicle with the plasma membrane involves the link-
ing of the plasma membrane proteins syntaxin and synap-
tosomal-associated protein 25 (SNAP-25) with the vesicle
protein vesicle-associated protein 2 (VAMP-2) or synapto-
brevin-2. Syntaxin and SNAP-25 are known as t-SNARE
and VAMP-2 is known as v-SNARE.
Insulin granule secretion in response to glucose stimula-
tion exhibits two characteristic phases. This biphasic pat-
tern consists of a rapidly initiated, but transient first phase
of insulin release, and a sustained second phase [48-50].
β Cells contain two pools of insulin containing secretory
granules that have distinct release processes. A limited
pool of granules (< 5%) is available for immediate release
and is referred to as the "readily releasable pool" (RRP).
However, most of the insulin granules (> 95%) belong to
a reserve pool and must undergo mobilization before they
can gain release competence [51-53]. The release of RRP
granules accounts for the first phase of insulin secretion.
The end of the first phase marked the depletion of this
pool. The subsequent granule re-supply or mobilization
from a reserve pool of granules and release of these mobi-
lized granules is responsible for the second-phase of insu-
lin secretion [54] (Figure 2).
Effects of glucose on insulin transcription, 
translation and release
Glucose controls all aspects of insulin regulation. Glucose
is the major physiologic regulator of insulin transcription,
translational regulation of insulin biosynthesis, and insu-
lin secretion. The response of β cells to glucose is complex.
Glucose has both immediate and long term effects that are
mediated on several levels including granule release, pro-
tein translation and mRNA transcription. β Cells have
large stores of insulin in granules and immediately fol-
lowing glucose stimulation a small proportion of these
granules are released. To renew these stores, insulin bio-
synthesis starts immediately and during this period after
glucose stimulation glucose-induced insulin biosynthesis
is regulated mainly at the translational level [55,56]. Dur-
ing this period glucose metabolism may be coupled to the
transcriptional activation of immediate-early response
factors. During periods of prolonged glucose stimulation
(> 12 h), glucose increases insulin biosynthesis by acceler-
ating insulin gene transcription, as well as by increasing
preproinsulin mRNA stability and protein translation.
Glucose control of insulin secretion
The mechanism by which glucose triggers insulin secre-
tion has been well established. β-cells do not release insu-
lin in response to glucose itself, but to glucose
metabolism [57]. Glucose enters β-cells via the GLUT 2
transporter. Intracellular glucose is then metabolized to
generate ATP. This results in an increase in the cytosolic
ATP: ADP ratio which in turn results in the closure of KATP-
channels, membrane depolarization, and initiation of
electrical activity [58].
Intracellular Ca2+ signaling plays a critical role in the reg-
ulation glucose-mediated insulin secretion. The depolari-
zation of the plasma membrane by the closure of the KATP
channels allows the opening of the L-type voltage depend-
ent Ca2+-channels (L-VDCC) which results in an increase
in the influx of calcium and an increase in the intracellular
Ca2+ concentration, an event that causes exocytosis of the
insulin granules [52]. This ATP-sensitive K+ (KATP) insulin
release pathway is also known as the triggering pathway.
SNARE proteins play a critical role in insulin granule
secretion [59,60]. The granule protein, v-SNARE, and the
β cell plasma membrane protein, t-SNARE, bring insulin
granules in close contact with the plasma membrane and
plasma membrane Ca 2+-channels [61]. When glucose
stimulation leads to the closure of KATP channels and the
opening of the Ca 2+-channels and the RRP granules
located just beneath the inner mouth of Ca 2+-channels
are exposed to high levels of Ca2+ causing RPR granule
release or exocytosis. The release of insulin RPR granules
proceeds in an essentially all-or-none fashion depending
on whether the Ca 2+-channels are open or not
[53,54,62,63].
Glucose also affects calcium influx via cyclin-dependent
kinase 5 kinase (Cdk5). Cdk5 phosphorylates the α1C sub-
unit of L-VDCC which decreases its activity by preventing
the binding of L-VDCC to the SNARE proteins. The activ-
ity of CdK5 kinase is dependent on glucose. High glucose
concentrations inhibit the Cdk5 kinase activity which in
turn increases the inward whole-cell Ca2+ channel current
and increases Ca2+influx, leading to enhanced insulin
secretion [64].
Glucose not only triggers insulin secretion but also ampli-
fies it. The amplifying effect of glucose on insulin release
is known as the augmentative pathway. This pathway does
not cause insulin secretion by itself, but it enhances Ca2+
mediated secretion. The augmentation pathway is inde-
pendent of KATP-channel inhibition. In fact, changes inJournal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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Insulin synthesis and secretion process Figure 2
Insulin synthesis and secretion process. After preproinsulin mRNA transcription, preproinsulin is synthesized in the ER 
and converted into proinsulin, proinsulin is transported through the Golgi apparatus and packaged into immature clathrin-
coated granules, where proinsulin is processed into insulin and c-peptide. The immature granules can then become mature 
granules containing cystalized insulin. After glucose stimulation insulin granules exhibit two characteristic phases that consist of 
a rapidly initiated but transient first phase and a sustained second phase, because the granules are divided into two different 
pools. (1) A limited pool of granules (< 5%) ready for immediate release and is referred to as the "readily releasable pool" 
(RRP), which account for the first release phase. (2) Most of the granules (> 95%) belong to a reserve pool responsible for the 
second-phase of insulin secretion, granules in this pool must undergo mobilization before they can gain release competence.Journal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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ADP concentration mediate the amplifying effect while
ATP represents a permissive factor [65,66].
Before insulin secretory granules can be released, they
must be primed or acidified. Insulin granule priming is
dependent on the simultaneous operation of a V-type H+-
ATPase and ClC-3 Cl- channels. Cl- ion uptake determines
the extent of granular acidification by providing a coun-
ter-ion required to allow continuous H+ pumping. The
activity of the ClC-3 Cl- channels is inhibited by high con-
centration of ADP. As a result of glucose metabolism, the
ADP level is decreased while ATP level is increased, lead-
ing to granular acidification. Acidification is a prerequisite
for insulin secretion and only after acidification, can gran-
ules undergo exocytosis whenever Ca 2+ influx increases to
exocytotic levels and thus insulin secretion is amplified
[67,68] (Figure 3).
Glucose control of insulin transcription
The β-cells contain a large pool of cytoplasmic insulin
mRNA which makes up 10 to15% of all the β cells' total
mRNA [69]. Even at low glucose concentrations large
quantities of insulin mRNA are present, however, at low
plasma glucose concentrations (< 3 mM) the insulin
mRNA reservoirs are due to basal insulin gene transcrip-
tion. At higher glucose concentrations insulin transcrip-
tion increases. For example, the mouse insulin gene
promoter is transcriptionally active in the absence of glu-
cose, but the addition of glucose stimulates transcription
about 3-fold after 10 minutes, and the stimulatory effect
is most pronounced 30 minutes after the glucose stimu-
lus, but declines thereafter [70]. However, the regulation
of insulin mRNA production is complex. No one factor
completely controls insulin gene expression and tran-
scription continues even when components involved in
the stimulus-dependent up-regulation of insulin gene
transcription are blocked or even knocked-out.
In addition to increasing the rate of insulin mRNA tran-
scription, glucose also prolongs the half-life of preproin-
sulin mRNA. The half-life of preproinsulin mRNA in cells
incubated in 17 mM of glucose is 76.8 hours, however,
the half-life of those islets incubated in 3.3 mM is 29.0
hours [71]. Other studies have found that in rat islets low-
ering glucose from 11 mM to 2 mM decreased insulin
mRNA levels by 38%, 79% and 66% at 3, 6 and 12 hours
respectively [72]. Another study found that the content of
preproinsulin mRNA in islets cultured at 3.3 mM glucose
was reduced to 10% of the control islets after 24 hours
and remained at that level for up to 7 days of incubation
[73]. This suggests that the lower glucose concentrations
may increase the proinsulin mRNA degradation rate.
The proinsulin mRNA 5' and 3' untranslated regions
(UTR) also act cooperatively to increase glucose-induced
preproinsulin biosynthesis [74]. Elements within the 3'
UTR stabilize the mRNA and those within the 5' UTR
stimulate preproinsulin translation. In addition, insulin
gene 5'-untranslated region alternative splicing has been
found in isolated human pancreatic islets, and the alterna-
tively sliced mRNA is translated twice as efficiently (in
vitro) as the native proinsulin mRNA. Twenty-four hours
of hyperglycemia increases the expression of the alterna-
tively spliced form by more than 2-fold and 72 hours of
hyperglycemia increases it by more than 10-fold, suggest-
ing that prolonged exposure to high glucose concentra-
tions may indirectly affect the insulin splicing process and
lead to the preferential use of the cryptic splice site [75].
The effect of short-term glucose stimulation on preproin-
sulin transcription is controversial. Isolated rat islets
exposed to 16.7 mM glucose for 1 hour and 3 hours did
not alter proinsulin mRNA levels, however, longer incu-
bations (6, 12, and 24 hours)increased proinsulin mRNA
levels 1.7-, 2.2-, and 2.6-foldi [76]. Similarly, incubating
rat islets for 1 hour in 16.7 mM glucose, compared to 2.8
mM glucose, resulted in similar preproinsulin mRNA lev-
els [77]. However, another study of rat islets found that
proinsulin biosynthetic rates increased within 1 hour of
exposure to high glucose concentrations, with fifty per-
cent of this increase attributed to preproinsulin gene tran-
scription. Furthermore, these investigators found that the
glucose stimulatory effect was short-lived; the transcrip-
tional activity was maximal at 30 minutes but markedly
decreased thereafter [78].
The apparently contradictory results may be due to the
dynamics of newly synthesized proinsulin mRNA, which
undergoes faster degradation than pre-existing proinsulin
mRNA [78]. Perhaps during 1-hour glucose stimulation,
newly synthesized preproinsulin mRNA is degraded so
rapidly that changes in preproinsulin mRNA levels are not
detectable. Another potential explanation is that although
glucose-induced insulin transcription can start within
minutes, the preproinsulin mRNA levels accumulate
slowly against the high background of steady-state mRNA.
Many factors contribute to glucose-induced insulin tran-
scription, including the transcription factors PDX-1 [79],
MafA [39,80,81], and a heterodimer (E12/E47 and E2/5)
and (BETA 2/NeuroD) [82,83] with the main glucose-
responsive elements on the insulin promoter, the A3 [84],
C1 and E1 [85] boxes. Insulin gene transcription is regu-
lated through the activation of these factors and in combi-
nation, these factors can exert strong synergistic effects
[37,86-88]. The upstream signaling that regulates these
factors begins with β cell glucose metabolism.
The most important effects of glucose on insulin transla-
tion appear to be mediated by PDX-1. Glucose effectsJournal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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Glucose control of insulin secretion Figure 3
Glucose control of insulin secretion. Glucose-stimulates insulin secretion via two mechanisms: the triggering pathway and 
the amplifying pathway. (1) Glucose enters beta cells through GLUT-2 and undergoes glycolysis. This metabolism increases the 
ratio of ATP to ADP, which inhibits the ATP-sensitive KATP-channels, leading to membrane depolarization and opening of volt-
age-dependent calcium channels (VDCC), with a resultant major increase in cytosolic calcium, which, in turn, triggers exocyto-
sis. SNARE proteins play a critical role in insulin granule secretion. The linking of the plasma membrane proteins syntaxin and 
SNAP-25 to vesicle protein VAMP-2/synaptobrevin-2 cause the docking of the vesicle, bringing insulin granules in close contact 
with the plasma membrane and calcium channels, after opening of calcium channels, the readily releasable pool (RRP) insulin 
granules located nearby are exposed to high level of Ca2+, resulting in RRP granule exocytosis. CDK5 can inhibit VDCC activ-
ity by phosphorylating its subunit, thus inhibiting insulin secretion; however, high glucose concentrations inhibit the Cdk5 
kinase activity which in turn increases Ca2+ influx, leading to enhanced insulin secretion. (2) Insulin granules in reserve pool 
must undergo acidification to gain secretion competence. This mobilization or priming process is dependent on the simultane-
ous operation of a V-type H+-ATPase and ClC-3 Cl- channels. Cl- uptake determines the extent of granular acidification by pro-
viding a counter-ion required to allow continuous H+ pumping. ADP can inhibit Cl- channel activity, however, glucose 
metabolism reduces the ADP level, leading to the loss of inhibition to Cl- channels, so insulin secretory granules undergo acid-
ification and the secretion process is augmented.Journal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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PDX-1 function in many different ways including a shift
in the cellular distribution of PDX-1 from the cytoplasm
to the nucleus, increases in the potential of the PDX-1 acti-
vation domain, and increases PDX1 binding to A3 [89-
94]. The effects of glucose on PDX-1 are, in part, due to the
phosphorylation of PDX-1 through the activation of
phosphatidylinositol 3-kinase (PI3-K), while stress-acti-
vated protein kinase 2 (SAPK2/P38) may also be involved
in this process [95], its function is controversial [96]. In
fact, the PI3-K kinase pathway is considered a central reg-
ulator of PDX-1 and of glucose-induced insulin gene tran-
scription [95,96]. Since PI3-K is a key molecule in the
insulin receptor pathway, the activation of insulin gene
transcription has been suggested, in part, to be the result
of a feed forward mechanism involving the binding of
secreted insulin to its receptor on the β cell surface [97-
99].
Glucose and PDX-1 also modulate insulin transcription
by influencing histones. When glucose levels are low,
PDX-1 interacts with histone deacetylases Hdac-1 and
Hdac-2, recruiting them to the insulin gene promoter
where they deacetylate histone H4 and thereby down-reg-
ulate insulin gene expression [100].
Glucose also increases bHLH heterodimer binding to the
E site. E47/BETA 2 is critical for glucose-induced insulin
gene transcription [101-103]. Stimulatory glucose con-
centrations can activate β cell ERK1/2, and ERK1/2 pro-
motes BETA 2 and E47 heterodimerization and binding to
E-box sites [104]. Blocking ERK1/2 activity using kinase-
defective ERK2 resulted in a substantial reduction in pre-
proinsulin mRNA content after 24 hours[104]. Both the
basal activity and the glucose-induced stimulation of the
A2-E1 region of the insulin promoter are critically
dependent upon ERK1/2 [105].
The mechanism by which MafA is activated by glucose is
distinct. While glucose induces post translation modifica-
tions of PDX-1 and the bHLH heterodimer, glucose
increases MafA transcription. At a glucose concentration
of 2.8 mM, MafA expression is undetectable in whole β
cell lysates. In contrast, at concentration of 16.7 mM MafA
protein is readily detected. Exposing islets to 16.7 mM glu-
cose for 24 hours also significantly increases MafA mRNA
expression [89]. (Figure 4).
Immediate-early response genes (IEGs) are also involved
with glucose mediated insulin biosythesis. IEGs are tran-
scription factors that activate expression of downstream
target genes, thus generating distinct biological responses
by inducing specific long-term gene expression programs.
In INS-1 β-like cells, glucose induces a Ca2+-dependent
transcriptional activation of several immediate early genes
such as c-fos, c-jun, JunB, zif-268 and nur-77 genes. In par-
ticular, c-fosand JunB proteins might facilitate glucose/
cAMP mediated insulin gene induction [106]. 15 minutes
of glucose stimulation induced egr-1 mRNA and protein
synthesis, with maximum levels achieved in 30 minutes,
in both glucose-responsive cell lines as well as primary
islets. Glucose stimulation also induced expression of c-fos
mRNA and JunB mRNA [107]. Thus, glucose metabolism
could be coupled to transcriptional activation of immedi-
ate-early response factors.
Prolonged glucose stimulation leads to an increase in
insulin transcription, which is supplementary to the glu-
cose-induced translational control of proinsulin biosyn-
thesis [77,108]. Under conditions of sustained secretory
drive, stimulation of proinsulin gene transcription by glu-
cose appears to be necessary for maintaining preproinsu-
lin biosynthesis and hence conserving pancreatic insulin
stores [108].
Glucose control of translation
After insulin is secreted in response to glucose stimula-
tion, renewed insulin biosynthesis begins immediately to
replenish the insulin stores. After short term (less than 2
hours) glucose stimulation, insulin biosynthesis is mainly
regulated at the translational level [55,109]. When pri-
mary rat islets are stimulated by high glucose for 1 hour,
preproinsulin biosynthesis increases 4-5 fold without any
change in the total preproinsulin mRNA level [77]. In
another study, preproinsulin biosynthesis increased 25-
fold when glucose increased from 1 to 10 mM [110].
The mechanism by which glucose regulates proinsulin
synthesis in β-cells remains unclear. It was previously
hypothesized that the insulin protein production increase
resulted from increased translation initiation, elongation
and signal recognition particle (SRP) release. Evidence has
shown however that translation elongation occurs only at
non-physiological glucose concentrations [56,111,112]
and does not play a major role in glucose-stimulated insu-
lin synthesis. Translation initiation is now thought to be
the primary mechanism underlying glucose stimulated
insulin synthesis.
Factors involved with glucose regulation of preproinsulin
translation initiation are the translation initiation factors
eIF4F, eIF2 and PERK [113,114]. The initiation complex
eIF4F initiates the recruitment of the 40 S ribosome pre-
requisite to mRNA in protein synthesis. Hypophosphor-
ylated eIF4E-binding proteins (4E-BPs) inhibit eIF4F
complex formation but phosphorylation of 4E-BP1
decreases this inhibition, thereby increasing mRNA trans-
lation [46,47]. In primary islets and pancreatic β-cell lines,
glucose increases 4E-BP1 phosphorylation [113], suggest-
ing the eIF4F assembly importance in glucose-stimulated
protein synthesis.Journal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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Glucose control of insulin gene transcription Figure 4
Glucose control of insulin gene transcription. Glucose metabolism in beta cells generates upstream signals that are 
responsible for the activation of factors involved in insulin transcription. (1) Glucose metabolism causes a shift of transcription 
factor PDX-1 from the cytoplasm to the nucleus, increases its activation domain and binding to A3 element. The effects are in 
part, due to the activity of phosphatidylinositol 3-kinase (PI3-K); another kinase stress-activated protein kinase 2 (SAPK2/P38) 
might be involved in this process. An alternative pathway involves histone and PDX-1. When glucose levels are low, PDX-1 
interacts with histone deacetylases Hdac-1 and Hdac-2 and recruits them to insulin gene promoter, which causes the 
deacetylation of histone H4 and results in down-regulation of insulin gene expression. High concentrations of glucose diminish 
this inhibiting activity. (2) Stimulatory concentrations of glucose can activate ERK1/2, which promotes BETA2 and E47 het-
erodimerization and binding to E-box sites. (3) Glucose affects MafA at the mRNA level. Stimulatory glucose levels increase 
MafA transcription and result in increased MafA protein.Journal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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Eukaryotic initiation factor 2 (eIF2) is another important
factor regulating protein biosynthesis, participating in
translational ternary complex (eIF2-GTP·Met-tRNAi) for-
mation. This complex assembles only if eIF2 is in its GTP-
bound state. After the formation of the 80S ribosome, the
GTP bound to eIF2 is then hydrolyzed to GDP. The recy-
cling of the inactive eIF2·GDP complex to the active
eIF2·GTP complex is catalyzed by the guanine nucleotide
exchange factor, eIF2B. eIF2B activity is transiently up-reg-
ulated in glucose stimulated isolated islets [111], suggest-
ing that eIF2B may be an important modulator of insulin
synthesis. Other studies suggest a role for the eIF2 alpha
subunit (eIF2α); phosphorylation of eIF2α inhibits ternary
complex formation, and glucose dephosphorylateseIF2α
thereby increasing translational ternary complex availa-
bility [114] (Figure 5).
Other genes and proteins affected by glucose
9Glucose also induces delayed long-term responses by
inducing the expression of other genes involved in β-cell
function such as glucose transporter 2 (GLUT-2), pyruvate
kinase, acetyl-coenzyme A-carboxylase [115-118]. The
Glucose control of insulin translation Figure 5
Glucose control of insulin translation. Glucose stimulates insulin synthesis largely by promoting insulin translation initia-
tion. (1) Glucose promotes the phosphorylation of eIF-4EBP and activates eIF-4E; eIF-4E, eIF-4A and eIF-4G form eIF-4F, a 
complex whose functions include recognition of preproinsulin mRNA and recruiting 40S ribosome to mRNA. (2) eIF2 is a crit-
ical factor regulating protein biosynthesis. It is active only in GTP-bound state. A factor named eIF-2B functions to convert 
GDP-bound eIF-2 to GTP-bound eIF-2. The activity of eIF-2B is transiently up-regulated after glucose stimulation. Additionally, 
phosphorylation of alpha subunit of eIF2 (eIF2α) inhibits the formation of eIF2-GTP·Met-tRNAi translational ternary complex, 
which binds 40S ribosome and is indispensable for protein translation. Glucose causes the dephosphorylation of eIF2α, and 
induces an increase in the availability of the translational ternary complex.Journal of Translational Medicine 2007, 5:1 http://www.translational-medicine.com/content/5/1/1
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expression of these genes is necessary to meet the
increased metabolic and secretory demands during
extended or repeated periods of hyperglycemia.
Conclusion
Islet transplantation has the potential to benefit patients
with type I diabetes, but it is a therapy limited by islet sup-
ply and other factors. While preliminary studies have
found that stem cells can be induced to acquire a β-cell-
like phenotype,, cells used for transplant therapy will
need precisely replicate β-cell function. Characterizing the
β-cell's unique molecular mechanisms underlying its glu-
cose responsivity will allow investigators to better under-
stand the critical elements stem cells must acquire and
may allow investigators to better direct stem cell differen-
tiation.
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